Marksans Pharma Ltd
NSE:MARKSANS
Marksans Pharma Ltd
Depreciation & Amortization
Marksans Pharma Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Marksans Pharma Ltd
NSE:MARKSANS
|
Depreciation & Amortization
-₹817m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-18%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Depreciation & Amortization
-₹16.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Depreciation & Amortization
-₹10.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Depreciation & Amortization
-₹25.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Depreciation & Amortization
-₹8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-18%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Depreciation & Amortization
-₹4B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Marksans Pharma Ltd
Glance View
Marksans Pharma Ltd. is a prominent player in the global pharmaceutical landscape, with its roots deeply embedded in the meticulous world of drug formulation and manufacturing. The company weaves its narrative through a robust portfolio that spans various therapeutic segments, including pain management, oncology, cardiovascular health, and anti-diabetic medications. By navigating the complexities of regulated markets such as the United States, the United Kingdom, and Australia, Marksans has engineered a business model that emphasizes quality, compliance, and innovation. This framework allows the company not only to design and develop a diverse array of generic pharmaceutical products but also to efficiently cater to a global clientele through its cost-effective yet high-quality manufacturing processes. Central to Marksans' success is its strategic integration of research and development with flexible manufacturing capabilities, housed in state-of-the-art facilities across Goa and India. These facilities, certified by leading international regulatory bodies, enable Marksans to maintain a competitive edge in both product delivery and diversification. By leveraging strategic partnerships and continuously expanding its product portfolio, it thrives in the dynamic pharmaceutical market. Revenue generation flows seamlessly through its vertically integrated operations, which streamline the journey from drug conception to distribution. Through these concerted efforts, Marksans not only bolsters its financial standing but also contributes significantly to the broader field of global healthcare, aligning economic performance with a commitment to health and well-being.
See Also
What is Marksans Pharma Ltd's Depreciation & Amortization?
Depreciation & Amortization
-817m
INR
Based on the financial report for Dec 31, 2024, Marksans Pharma Ltd's Depreciation & Amortization amounts to -817m INR.
What is Marksans Pharma Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-18%
Over the last year, the Depreciation & Amortization growth was -22%. The average annual Depreciation & Amortization growth rates for Marksans Pharma Ltd have been -49% over the past three years , -29% over the past five years , and -18% over the past ten years .
You don't have any saved screeners yet